Individual Patient Access to AbbVie ABT-450/ritopnavir/ABT-267 and ABT-333 Coadministeres with ribavirin (RBV) in Adult Liver Transplant Recipient with Genotype 1 Hepatitis C Virus Infection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-004268-38-HU

Enrollment

Registered

2014-10-02

Start date

2014-10-27

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MedDRA version: 17.0 Level: LLT Classification code 10072848 Term: Hepatitis C virus genotype 1 positive System Organ Class: 100000004848 MedDRA version: 17.0 Level: LLT Classification code 10024716 Term: Liver transplantation System Organ Class: 100000004865

Interventions

Product Name: ABT-450/ritonavir/ABT-267 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: ABT-450 Current Sponsor code: ABT-450 Other descriptive name: ABT-450 Concentration unit: mg millig

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 1 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: The objective of treatment with this regine is to obtain sustained virologic response of recurrent hepatitis c virus in a post-liver transtplantation with HCV infection.;Secondary Objective: ;Primary end point(s):	—

Countries

Hungary

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026